(Total Views: 611)
Posted On: 06/03/2019 6:18:01 PM
Post# of 30015
Dr. Herman Weiss, Chief Executive Officer of Todos Medical. “We believe that our target of bringing the TM-B1 blood test to be accepted as a standard of care test for general breast cancer screening worldwide remains the long-term goal for Todos. We are pleased with the results as they demonstrate TM-B1’s accuracy in the Asian population, where it is estimated that women have the highest rate of dense breast tissue. These results are comparable to those we received in our Israeli trials for the same test and provides a strong support for the further development of our TBIA platform in other cancer indications, like our TM-C1 for colon cancer detection.”
Some big news today!
Aloha
Some big news today!
Aloha
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)